In light of the growing global and regional attention to prostate cancer as one of the key health challenges facing men, Bayer highlighted the importance of raising awareness of the disease, encouraging early diagnosis, and keeping pace with scientific developments that contribute to improving patient care and supporting their treatment journey.
This comes amid the increasing need to enhance public knowledge of prostate cancer, as one of the most common types of cancer among men, where awareness of symptoms and risk factors, alongside regular medical follow-up, contributes to improving the chances of early detection and more effective disease management.
During a scientific symposium held at the Grand Egyptian Museum, attended by a distinguished group of oncologists and urologists from across the region, Bayer highlighted a new use of NUBEQA, as one of the potential future applications aimed at changing the treatment journey for metastatic hormone-sensitive prostate cancer through the results of new studies. It can be used with androgen deprivation therapy alone or in combination with docetaxel, giving physicians greater flexibility in making treatment decisions according to each patient’s health condition and the suitability of the available treatment options.
Participants emphasized that managing prostate cancer is no longer limited to traditional therapeutic intervention only, but has become based on a more comprehensive vision that takes into consideration the nature of each case, the stage of the disease, and the patient’s overall health condition, allowing for more personalized treatment plans to support the best possible outcomes.
For his part, Dr. Mohamed Abdullah, Professor of Clinical Oncology at Cairo University, said:
“Scientific developments in the treatment of prostate cancer have today provided physicians with more flexible and personalized treatment options, allowing treatment decisions to be made in line with the nature of the disease in each patient and its clinical stage.”
Uwe Dalichow, Head of EMEA Region, Pharmaceuticals Division at Bayer, stated:
“At Bayer, we believe that supporting patients starts with awareness and knowledge, and extends to keeping pace with scientific developments that contribute to improving patient care. Through supporting scientific dialogue and health education, we continue our commitment to contributing to raising awareness of prostate cancer and improving the patient journey in Egypt and the region.”
Prostate cancer is receiving increasing attention within public health priorities, amid the need to encourage men to seek medical advice at the right time and overcome delays in diagnosis caused by lack of awareness or hesitation in following up on symptoms, contributing to improved long-term health outcomes.
Through this approach, Bayer reaffirms its continued commitment to supporting health awareness, strengthening constructive scientific dialogue with the medical community, and contributing to the development of prostate cancer patient care, combining health education and modern therapeutic developments for the benefit of patients and society.